Long-Term Effectivenss of Dopamine Agonists and Monoamine Oxidase B Inhibitors Compared with Levodopa as Initial Treatment for Parkinsons Disease (PD MED): A Large, Open-Label, Pragmatic Randomised Trial
Lancet 383: Doi: 10.1016/S0140-6736, PD MED Collaborative Group, 2014
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations
Arch Neurol 62:241-248, The PRESTO Study, 2005
Rasagiline as an Adjunct to Levodopa in Patients With Parkinsons Disease and Motor Fluctuations (LARGO, Lasting Effect in Adjunct Therapy With Rasagiline Given Once Daily, Study)
Lancet 365:947-954, 914, Rascol,O., et al, 2005
Comparison of Therapeutic Effects & Mortality Data of Levodopa & Levodopa with Selegiline in Pts with Early, Mild Parkinson's
BMJ 311:1602-1607, 15831995., Lee,A.J.,et al, 1995
Deprenyl Effects of Levodopa Pharmacodynamics, Mood, and Free Radical Scavenging
Neurol 42:541-544, Baronti,F.,et al, 1992
Considerations in the Management of Parkinsonism
Neurol 28:5, Fahn,S.,et al, 1978
Newer Concepts in Management of Migraine Headaches
J Med Soc N J 74:11, Haidri,N.H.,et al, 1977
Postural Hypotension:Adrenergic Responsivity, & Levodopa Therapy
Neurol 27:921, Corder,C.N.,et al, 1977
Drug Therapy of Parkinsonism
NEJM 295:814, Bianchine,J.R., 1976
Drug Therapy of Parkinsonism
NEJM 287:20, Yahr,M.,et al, 1972
Monoamine Oxidase Inhibitor & L-Dopa
BMJ 3:388, Hunter,H.R.,et al, 1970
Neuropsychopharmcology & the Affective Disorders
NEJM 281:197, 1969 (three parts) ., Schildkraut,J.J., 1969
Neurotoxicity of Commonly Used Antineoplastic Agents
NEJM 291:75, 1271974., Weiss,H.,et al, 1974